Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

NCT00338299 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Chemotherapy

Interventions

DRUG: Epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]